April 13, 2015 3:37 pm by Meghana Keshavan | 0 Comments MedCity News <\/p>\n
Cambridge gene therapy startup Voyager Therapeuticsjust wrapped up a $60 million Series B round to advance its treatments for conditions of the CNS like ALS and Parkinsons disease. Voyager is using the money to advance its five clinical and preclinical programs, as well as a platform developed around adeno-associated viruses. <\/p>\n
New investors include Brookside Capital and Partner Fund Management, with participation from Wellington Management, Casdin Capital and two undisclosed blue chip investment funds. This roundsright on the heels of an impressive $45 million Series A from Third Rock, which was completed just about a year ago as the company launched. <\/p>\n
Voyagers gene therapiesare in different stages of completion, with its Parkinsons therapy the most advanced: <\/p>\n<\/p>\n
Get our daily newsletter or follow us. <\/p>\n
Please enter your email below: <\/p>\n
<\/p>\n
Read the original post: <\/p>\n
Cambridge gene therapy startup Voyager Therapeutics raises $60M for CNS disorders<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" April 13, 2015 3:37 pm by Meghana Keshavan | 0 Comments MedCity News Cambridge gene therapy startup Voyager Therapeuticsjust wrapped up a $60 million Series B round to advance its treatments for conditions of the CNS like ALS and Parkinsons disease. Continue reading